NVP-BEP800, also known as BEP-800, is a small molecule inhibitor of heat shock protein 90 (HSP90), which is a molecular chaperone involved in the folding and stabilization of various proteins. It was first discovered in 2004 and has since been studied for its potential as a treatment for various types of cancer.
Chemical name:
The chemical name for NVP-BEP800 is 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione.
Molecular formula:
The molecular formula of NVP-BEP800 is C24H29N5O3S.
Formula weight:
The formula weight of NVP-BEP800 is 471.59 g/mol.
CAS No:
The CAS number of NVP-BEP800 is 847559-80-2.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
NVP-BEP800 has been primarily developed for the treatment of cancer. It is an inhibitor of HSP90, which is a molecular chaperone involved in the folding and stabilization of various proteins, including those involved in cancer cell growth and survival. By inhibiting HSP90, NVP-BEP800 may induce cancer cell death and inhibit their proliferation.
Potential effects:
Some potential effects of NVP-BEP800 include:
Product mechanism:
NVP-BEP800 works by inhibiting HSP90, which is a molecular chaperone involved in the folding and stabilization of various proteins, including those involved in cancer cell growth and survival. By inhibiting HSP90, NVP-BEP800 can induce protein misfolding and degradation, leading to cancer cell death and inhibition of their proliferation.
Safety:
NVP-BEP800 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with NVP-BEP800.
Side effects:
NVP-BEP800 can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of NVP-BEP800 has not yet been established and further research is needed to determine the most effective dose. In preclinical studies, doses ranged from 5 to 100 mg/kg. In clinical trials, doses ranged from 50 to 200 mg once daily. The drug is typically administered orally.
Conclusion:
NVP-BEP800 is a small molecule inhibitor of HSP90 that has shown potential as a treatment for various types of cancer. By inhibiting HSP90, NVP-BEP800 may induce cancer cell death and inhibit their proliferation. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of NVP-BEP800 in treating various types of cancer
